A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Placebo for the Extended Prevention of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery.
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Semuloparin (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Registrational; Therapeutic Use
- Acronyms SAVE-HIP3
- Sponsors Sanofi
- 04 Mar 2010 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India.
- 03 Feb 2010 New source identified and integrated (Clinical Trials Registry - India; CTRI2009-091-000550)
- 20 Jan 2010 Additional trial location identified as reported by ClinicalTrials.gov.